What is Closed Loop Medicine?
Closed Loop Medicine is a therapeutics company based in Cambridge, UK, specializing in innovative care pathways, outcome optimization, and the provision of dynamic, personalized treatment regimens. The company's development pipeline uniquely integrates drug therapies with digital tools and devices to address major global health challenges. Currently, Closed Loop Medicine is focusing its efforts on treating sleep disorders and hypertension, with plans to expand its therapeutic scope to other significant health issues in the future.
How much funding has Closed Loop Medicine raised?
Closed Loop Medicine has raised a total of $21.9M across 3 funding rounds:
Other Financing Round
$3.9M
Grant
$319K
Unspecified
$17.6M
Other Financing Round (2020): $3.9M with participation from IQ Capital, Martlet, BGF, Longwall Ventures, and Cambridge Angels
Grant (2020): $319K, investors not publicly disclosed
Unspecified (2021): $17.6M, investors not publicly disclosed
Key Investors in Closed Loop Medicine
IQ Capital
IQ Capital is a venture capital firm specializing in 'deep-tech' investments, including AI, machine learning, and advanced engineering, with a focus on companies capable of global market dominance. They invest from seed to Series A and have a strong track record of successful exits.
Martlet
Martlet appears to be an angel investment group, potentially focusing on early-stage ventures, as indicated by its domain and typical angel investor profiles. Their involvement suggests a belief in the foundational potential of Closed Loop Medicine's technology.
BGF
BGF is a prominent UK investor focused on supporting small and mid-sized businesses across various sectors and stages of growth, providing capital to fuel expansion and development.
What's next for Closed Loop Medicine?
The substantial enterprise-level investment in Closed Loop Medicine signals a strategic move towards scaling its integrated Drug + Digital + Device model. This capital infusion is expected to accelerate the company's research and development efforts, potentially expanding its pipeline beyond sleep disorders and hypertension into other critical health areas. The focus on dynamic personalized regimens suggests a future where treatment is highly adaptive to individual patient needs, leveraging both pharmaceutical and digital interventions for enhanced outcomes.
See full Closed Loop Medicine company page
